Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis

Published:2019-06 Issue:6 Volume:48 Page:967-975
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Quistrebert Jocelyn^ORCID,Hässler Signe^ORCID,Bachelet Delphine,Mbogning Cyprien,Musters Anne,Tak Paul Peter,Wijbrandts Carla Ann,Herenius Marieke,Bergstra Sytske Anne,Akdemir Gülşah^ORCID,Johannesson Martina,Combe Bernard,Fautrel Bruno,Chollet-Martin Sylvie^ORCID,Gleizes Aude,Donnellan Naoimh,Deisenhammer Florian,Davidson Julie,Hincelin-Mery Agnès,Dönnes Pierre,Fogdell-Hahn Anna,De Vries Niek,Huizinga Tom,Abugessaisa Imad^ORCID,Saevarsdottir Saedis,Hacein-Bey-Abina Salima,Pallardy Marc,Broët Philippe,Mariette Xavier

Funder

Seventh Framework Programme

Innovative Medicines Initiative

Illinois Department of Public Health

Centre Hospitalier Universitaire de Clermont-Ferrand

AbbVie

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference58 articles.

1. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

2. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab;Neovius;Ann Rheum Dis,2015

3. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

4. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up;Bartelds;JAMA,2011

5. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis;Wolbink;Arthritis Rheum,2006

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Personalized Medicine in Rheumatoid Arthritis;Open Access Rheumatology: Research and Reviews;2024-05

2. Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report;Biomedicines;2024-04-03

3. Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument;Practical Laboratory Medicine;2024-03

4. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression;Annals of the Rheumatic Diseases;2024-01-17

5. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review;Journal for ImmunoTherapy of Cancer;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3